Additionally, the 36-month beta value for TCRX is 0.45. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The average price predicted by analysts for TCRX is $11.25, which is $6.64 above the current price. The public float for TCRX is 38.50M and currently, short sellers hold a 1.22% ratio of that float. The average trading volume of TCRX on November 21, 2023 was 108.66K shares.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


TCRX) stock’s latest price update

Tscan Therapeutics Inc (NASDAQ: TCRX)’s stock price has gone decline by -13.83 in comparison to its previous close of 5.35, however, the company has experienced a 1.99% increase in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-20 that TScan Therapeutics, Inc. (TCRX) made it through our “Recent Price Strength” screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

TCRX’s Market Performance

Tscan Therapeutics Inc (TCRX) has experienced a 1.99% rise in stock performance for the past week, with a 46.35% rise in the past month, and a 121.63% rise in the past quarter. The volatility ratio for the week is 12.71%, and the volatility levels for the past 30 days are at 11.45% for TCRX. The simple moving average for the past 20 days is 12.41% for TCRX’s stock, with a 67.96% simple moving average for the past 200 days.

Analysts’ Opinion of TCRX

Many brokerage firms have already submitted their reports for TCRX stocks, with Wedbush repeating the rating for TCRX by listing it as a “Outperform.” The predicted price for TCRX in the upcoming period, according to Wedbush is $8 based on the research report published on June 22, 2023 of the current year 2023.

TCRX Trading at 34.44% from the 50-Day Moving Average

After a stumble in the market that brought TCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.55% of loss for the given period.

Volatility was left at 11.45%, however, over the last 30 days, the volatility rate increased by 12.71%, as shares surge +50.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +77.31% upper at present.

During the last 5 trading sessions, TCRX rose by +1.99%, which changed the moving average for the period of 200-days by +154.70% in comparison to the 20-day moving average, which settled at $4.18. In addition, Tscan Therapeutics Inc saw 197.42% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TCRX starting from BARBERICH TIMOTHY J, who purchase 37,880 shares at the price of $2.63 back on Jun 02. After this action, BARBERICH TIMOTHY J now owns 37,880 shares of Tscan Therapeutics Inc, valued at $99,564 using the latest closing price.

Lynx1 Capital Management LP, the 10% Owner of Tscan Therapeutics Inc, sale 25,400 shares at $2.52 during a trade that took place back on May 31, which means that Lynx1 Capital Management LP is holding 5,224,600 shares at $63,952 based on the most recent closing price.

Stock Fundamentals for TCRX

Current profitability levels for the company are sitting at:

The net margin for Tscan Therapeutics Inc stands at -489.26. The total capital return value is set at -37.84, while invested capital returns managed to touch -38.18. Equity return is now at value -61.85, with -38.67 for asset returns.

Based on Tscan Therapeutics Inc (TCRX), the company’s capital structure generated 86.47 points at debt to equity in total, while total debt to capital is 46.37. Total debt to assets is 43.19, with long-term debt to equity ratio resting at 82.77. Finally, the long-term debt to capital ratio is 44.39.

When we switch over and look at the enterprise to sales, we see a ratio of 11.75, with the company’s debt to enterprise value settled at 26.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.17.


In conclusion, Tscan Therapeutics Inc (TCRX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.